Illumina, Inc. $ILMN Stock Holdings Lessened by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 91.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 32,481 shares of the life sciences company’s stock after selling 356,518 shares during the period. Assenagon Asset Management S.A.’s holdings in Illumina were worth $3,085,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its stake in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares during the period. Rise Advisors LLC lifted its holdings in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares during the last quarter. Cullen Frost Bankers Inc. bought a new stake in shares of Illumina in the 2nd quarter worth approximately $41,000. NewSquare Capital LLC boosted its position in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares during the period. Finally, Evelyn Partners Investment Management LLP grew its stake in Illumina by 4,927.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after buying an additional 542 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 2.1%

Shares of NASDAQ:ILMN opened at $137.60 on Tuesday. The company has a 50 day moving average of $119.08 and a 200-day moving average of $105.03. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The firm has a market cap of $21.03 billion, a P/E ratio of 30.85, a P/E/G ratio of 2.41 and a beta of 1.44. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the acquisition, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.17% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ILMN. Evercore ISI raised their target price on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. UBS Group lifted their price objective on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. Barclays raised their price target on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Finally, TD Cowen lifted their price target on Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $118.31.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.